DeuterOncology SA
DeuterOncology reported total assets of 688,028 € at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jun 2026).
By total assets for 2025, DeuterOncology ranks in the top half of the 327 companies in its sector (NACE 2110) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of DeuterOncology shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -81 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
DeuterOncology's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
- Year ended 31 Dec 2023filed on 20 Jun 2024
- Year ended 31 Dec 2022filed on 07 Jul 2023
- Year ended 31 Dec 2021filed on 15 Sep 2022
DeuterOncology's financial analysis
- Solvency-383.0%sector median: 38.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of DeuterOncology
DeuterOncology's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0754.971.388
- VAT number
- BE0754971388
- Peppol
- Registered · 0208:0754971388 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 28 Sep 2020
- Registered office
- 4000 Liège
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
DeuterOncology (SA) has been based in Liège since 2020, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of €3.60m and equity of −€2.64m; its revenue is not published. Its solvency stands at -383.0%, below the median of its sector (38.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to DeuterOncology
Companies in the same business, of comparable size and area, outside its group.
- Shant Laboratories Belgium Manufacture of basic pharmaceutical products Tubize · balance sheet €1.06m
- Plant Bio Technologies Manufacture of basic pharmaceutical products Ghent · balance sheet €1.04m
- Intibio Manufacture of pharmaceutical preparations Bree · balance sheet 407,778 €
- Galenicap Manufacture of basic pharmaceutical products Ixelles · balance sheet €1.47m
- Clinical Research Vanackere Manufacture of basic pharmaceutical products Tielt-Winge · balance sheet 263,927 €
- OLYS Pharma Manufacture of pharmaceutical preparations La Hulpe · balance sheet €1.03m
- Make IT Work Consulting Manufacture of basic pharmaceutical products Hamois · balance sheet 220,980 €
- Curium PET Liège Manufacture of basic pharmaceutical products Liège · balance sheet €1.86m
Frequently asked questions about DeuterOncology
What is the revenue of DeuterOncology?
DeuterOncology files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of DeuterOncology?
In Belgium, the VAT number is the company number prefixed with BE: BE0754971388 for DeuterOncology, if the company is VAT-registered. Its company number (CBE) is 0754.971.388.
Where is the registered office of DeuterOncology?
According to the CBE register, the registered office of DeuterOncology is in 4000 Liège.
What is the equity of DeuterOncology?
At the close of the 2025 financial year, the equity of DeuterOncology amounts to -2,635,237 €, a solvency of -383.0% of total assets.
Who manages DeuterOncology?
The register lists 7 active mandates at DeuterOncology. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is DeuterOncology within its sector?
By total assets for 2025, DeuterOncology ranks in the top half of the 327 companies in its sector (NACE 2110) in Belgium that filed accounts for that financial year.
The full file of DeuterOncology
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →